HRP20140716T1 - Analozi oksitocina - Google Patents
Analozi oksitocina Download PDFInfo
- Publication number
- HRP20140716T1 HRP20140716T1 HRP20140716AT HRP20140716T HRP20140716T1 HR P20140716 T1 HRP20140716 T1 HR P20140716T1 HR P20140716A T HRP20140716A T HR P20140716AT HR P20140716 T HRP20140716 T HR P20140716T HR P20140716 T1 HRP20140716 T1 HR P20140716T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- image
- pain
- conditions
- connection
- Prior art date
Links
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 10
- 208000019901 Anxiety disease Diseases 0.000 claims 4
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 4
- 208000004998 Abdominal Pain Diseases 0.000 claims 2
- 206010003805 Autism Diseases 0.000 claims 2
- 208000020706 Autistic disease Diseases 0.000 claims 2
- 208000008035 Back Pain Diseases 0.000 claims 2
- 206010010774 Constipation Diseases 0.000 claims 2
- 206010057671 Female sexual dysfunction Diseases 0.000 claims 2
- 206010061974 Gastrointestinal obstruction Diseases 0.000 claims 2
- 208000032843 Hemorrhage Diseases 0.000 claims 2
- 206010021718 Induced labour Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010057672 Male sexual dysfunction Diseases 0.000 claims 2
- 208000001132 Osteoporosis Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 208000018525 Postpartum Hemorrhage Diseases 0.000 claims 2
- 208000036064 Surgical Blood Loss Diseases 0.000 claims 2
- 208000010238 Uterine Inertia Diseases 0.000 claims 2
- 206010046763 Uterine atony Diseases 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 208000034158 bleeding Diseases 0.000 claims 2
- 230000000740 bleeding effect Effects 0.000 claims 2
- 230000001771 impaired effect Effects 0.000 claims 2
- 208000015181 infectious disease Diseases 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 208000004396 mastitis Diseases 0.000 claims 2
- 230000036407 pain Effects 0.000 claims 2
- 230000003169 placental effect Effects 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 claims 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 claims 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 claims 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 claims 1
- YJLIKUSWRSEPSM-WGQQHEPDSA-N (2r,3r,4s,5r)-2-[6-amino-8-[(4-phenylphenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol Chemical compound C=1C=C(C=2C=CC=CC=2)C=CC=1CNC1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O YJLIKUSWRSEPSM-WGQQHEPDSA-N 0.000 claims 1
- VIJSPAIQWVPKQZ-BLECARSGSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-acetamido-5-(diaminomethylideneamino)pentanoyl]amino]-4-methylpentanoyl]amino]-4,4-dimethylpentanoyl]amino]-4-methylpentanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(C)=O VIJSPAIQWVPKQZ-BLECARSGSA-N 0.000 claims 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 claims 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 claims 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 claims 1
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 claims 1
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 claims 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 claims 1
- OMBVEVHRIQULKW-DNQXCXABSA-M (3r,5r)-7-[3-(4-fluorophenyl)-8-oxo-7-phenyl-1-propan-2-yl-5,6-dihydro-4h-pyrrolo[2,3-c]azepin-2-yl]-3,5-dihydroxyheptanoate Chemical compound O=C1C=2N(C(C)C)C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C(C=3C=CC(F)=CC=3)C=2CCCN1C1=CC=CC=C1 OMBVEVHRIQULKW-DNQXCXABSA-M 0.000 claims 1
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 claims 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 claims 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 claims 1
- LFOIDLOIBZFWDO-UHFFFAOYSA-N 2-methoxy-6-[6-methoxy-4-[(3-phenylmethoxyphenyl)methoxy]-1-benzofuran-2-yl]imidazo[2,1-b][1,3,4]thiadiazole Chemical compound N1=C2SC(OC)=NN2C=C1C(OC1=CC(OC)=C2)=CC1=C2OCC(C=1)=CC=CC=1OCC1=CC=CC=C1 LFOIDLOIBZFWDO-UHFFFAOYSA-N 0.000 claims 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 claims 1
- 229940127007 Compound 39 Drugs 0.000 claims 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 claims 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000003054 catalyst Substances 0.000 claims 1
- 229940125797 compound 12 Drugs 0.000 claims 1
- 229940126543 compound 14 Drugs 0.000 claims 1
- 229940125758 compound 15 Drugs 0.000 claims 1
- 229940126142 compound 16 Drugs 0.000 claims 1
- 229940125810 compound 20 Drugs 0.000 claims 1
- 229940125846 compound 25 Drugs 0.000 claims 1
- 229940125878 compound 36 Drugs 0.000 claims 1
- 229940126540 compound 41 Drugs 0.000 claims 1
- 229940125936 compound 42 Drugs 0.000 claims 1
- 229940125844 compound 46 Drugs 0.000 claims 1
- 229940127271 compound 49 Drugs 0.000 claims 1
- 229940126545 compound 53 Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 claims 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- FDBYIYFVSAHJLY-UHFFFAOYSA-N resmetirom Chemical compound N1C(=O)C(C(C)C)=CC(OC=2C(=CC(=CC=2Cl)N2C(NC(=O)C(C#N)=N2)=O)Cl)=N1 FDBYIYFVSAHJLY-UHFFFAOYSA-N 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/16—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Reproductive Health (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Pregnancy & Childbirth (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Claims (7)
1. Spoj izabran iz skupine koju čine: spoj 11
[image]
spoj 12
[image]
spoj 14
[image]
spoj 15
[image]
spoj 16
[image]
spoj 19
[image]
spoj 20
[image]
spoj 24
[image]
spoj 25
[image]
spoj 26
[image]
spoj 31
[image]
spoj 36
[image]
spoj 39
[image]
spoj 40
[image]
spoj 41
[image]
spoj 42
[image]
spoj 44
[image]
spoj 45
[image]
spoj 46
[image]
spoj 47
[image]
spoj 48
[image]
spoj 49
[image]
spoj 50
[image]
spoj 51
[image]
spoj 52
[image]
spoj 53
[image]
spoj 54
[image]
2. Spoj prema zahtjevu 1, naznačen time da je spoj izabran iz skupine koju čine.
[image]
[image]
3. Spoj prema zahtjevu 1, naznačen time da je spoj:
[image]
4. Spoj prema bilo kojem od zahtjeva 1-3, naznačen time da se upotrebljava kao farmaceutik.
5. Farmaceutska smjesa koja sadrži spoj prema bilo kojem od zahtjeva 1-3, naznačena time da je kao aktivni sastojak u vezi s farmaceutski prihvatljivim katalizatorom, otapalom ili nosačem.
6. Spoj prema bilo kojem od zahtjeva 1-3, naznačen time da se upotrebljava u liječenju jednog ili više narušenih uvjeta dojenja, oštećenja nakon induciranog poroda, uvjeta atonije maternice, pretjeranog krvarenja, upale, boli, abdominalne boli, boli leđa, muške i ženske seksualne disfunkcije, sindroma iritabilnog crijeva (IBS), zatvora, gastrointenstinalnog začepljenja, autizma, stresa, anksioznosti, depresije, poremećaja anksioznosti, gubitka krvi uslijed kirurških zahvata, postporođajnog krvarenja, zacjeljivanja rana, infekcije, mastitisa, oštećenja porođajne posteljice i osteoporoze.
7. Uporaba spoja prema bilo kojem od zahtjeva 1-3, naznačen time da se upotrebljava za pripremu lijeka za liječenje narušenih uvjeta dojenja, oštećenja nakon induciranog poroda, uvjeta atonije maternice, pretjeranog krvarenja, upale, boli, abdominalne boli, boli leđa, muške i ženske seksualne disfunkcije, sindroma iritabilnog crijeva (IBS), zatvora, gastrointenstinalnog začepljenja, autizma, stresa, anksioznosti, depresije, poremećaja anksioznosti, gubitka krvi uslijed kirurških zahvata, postporođajnog krvarenja, zacjeljivanja rana, infekcije, mastitisa, oštećenja porođajne posteljice i osteoporoze.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4097308P | 2008-03-31 | 2008-03-31 | |
EP08251739 | 2008-05-19 | ||
PCT/IB2009/005351 WO2009122285A1 (en) | 2008-03-31 | 2009-03-30 | Oxitocin analogues |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20140716T1 true HRP20140716T1 (hr) | 2014-08-29 |
Family
ID=39722695
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20140716AT HRP20140716T1 (hr) | 2008-03-31 | 2014-07-25 | Analozi oksitocina |
Country Status (21)
Country | Link |
---|---|
US (1) | US8673841B2 (hr) |
EP (2) | EP2626364A1 (hr) |
JP (1) | JP5539310B2 (hr) |
KR (1) | KR101558404B1 (hr) |
CN (1) | CN101983205B (hr) |
AU (1) | AU2009233429B2 (hr) |
BR (1) | BRPI0910345B1 (hr) |
CA (1) | CA2718148C (hr) |
DK (1) | DK2260053T3 (hr) |
ES (1) | ES2488992T3 (hr) |
HK (1) | HK1146064A1 (hr) |
HR (1) | HRP20140716T1 (hr) |
IL (1) | IL208039A (hr) |
MX (1) | MX2010010743A (hr) |
NZ (1) | NZ587817A (hr) |
PL (1) | PL2260053T3 (hr) |
PT (1) | PT2260053E (hr) |
RU (1) | RU2496788C2 (hr) |
SI (1) | SI2260053T1 (hr) |
WO (1) | WO2009122285A1 (hr) |
ZA (1) | ZA201006733B (hr) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2575853B1 (en) | 2010-05-25 | 2016-08-24 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods and pharmaceutical composition for the treatment of a feeding disorder with early-onset in a patient |
JO3400B1 (ar) * | 2010-09-30 | 2019-10-20 | Ferring Bv | مركب صيدلاني من كاربيتوسين |
JP6067878B2 (ja) | 2012-12-21 | 2017-01-25 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | オキシトシンアゴニストとしてのペプチド |
CN106414479B (zh) * | 2014-06-03 | 2021-08-03 | 豪夫迈·罗氏有限公司 | 作为催产素激动剂的肽 |
CR20160562A (es) * | 2014-06-06 | 2017-01-06 | Hoffmann La Roche | Péptidos como agonistas de la oxitocina |
US10588980B2 (en) | 2014-06-23 | 2020-03-17 | Novartis Ag | Fatty acids and their use in conjugation to biomolecules |
HRP20240166T1 (hr) | 2014-09-19 | 2024-04-26 | Ferring B.V. | Postupak liječenja prader-willijevog sindroma |
CN106084015B (zh) * | 2016-08-25 | 2020-01-31 | 成都圣诺生物制药有限公司 | 一种合成卡贝缩宫素的方法 |
US20190135859A1 (en) | 2017-08-11 | 2019-05-09 | Ferring B.V. | Method of manufacturing a pharmaceutical composition |
AU2018312956B2 (en) | 2017-08-11 | 2022-03-10 | Ferring B.V. | Method of manufacturing a pharmaceutical composition |
CN107628975B (zh) * | 2017-09-17 | 2019-10-29 | 贵州医科大学 | 赖氨酸衍生物类组蛋白去乙酰化酶抑制剂及其合成和应用 |
TW202031283A (zh) | 2018-09-20 | 2020-09-01 | 馬克 C 曼寧 | 穩定卡貝縮宮素鼻內製劑 |
EP3852724A4 (en) | 2018-09-20 | 2022-07-06 | Levo Therapeutics, Inc. | CARBETOCIN DRUG PRODUCT AND PROCESS FOR ITS MANUFACTURE |
JP7390031B2 (ja) | 2018-12-27 | 2023-12-01 | 国立大学法人金沢大学 | オキシトシン誘導体及びその使用 |
JP2023500763A (ja) | 2019-11-04 | 2023-01-11 | フェリング ベスローテン フェンノートシャップ | 泌乳の改善のためのメロトシンの鼻腔内投与 |
WO2022026463A1 (en) * | 2020-07-27 | 2022-02-03 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Oxytocin analogues and methods for using the same |
KR20240007126A (ko) | 2021-03-26 | 2024-01-16 | 오티4비 | 연하곤란의 치료 |
WO2024044633A2 (en) * | 2022-08-23 | 2024-02-29 | Seattle Children's Hospital (D/B/A Seattle Children's Research Institute) | Oxytocin derivatives and methods of use |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE9604341D0 (sv) * | 1996-11-26 | 1996-11-26 | Ferring Bv | Hepta-peptide oxytocin analogue |
DE60309847T2 (de) | 2002-02-27 | 2007-10-18 | Ferring B.V. | Zwischenprodukte und verfahren zur herstellung von heptapeptid-oxytocinanaloga |
-
2009
- 2009-03-30 MX MX2010010743A patent/MX2010010743A/es active IP Right Grant
- 2009-03-30 ES ES09727031.8T patent/ES2488992T3/es active Active
- 2009-03-30 BR BRPI0910345-7A patent/BRPI0910345B1/pt active IP Right Grant
- 2009-03-30 KR KR1020107024207A patent/KR101558404B1/ko active IP Right Grant
- 2009-03-30 AU AU2009233429A patent/AU2009233429B2/en active Active
- 2009-03-30 EP EP13156710.9A patent/EP2626364A1/en not_active Withdrawn
- 2009-03-30 NZ NZ587817A patent/NZ587817A/en unknown
- 2009-03-30 JP JP2011502454A patent/JP5539310B2/ja active Active
- 2009-03-30 CN CN200980111919.5A patent/CN101983205B/zh active Active
- 2009-03-30 PT PT97270318T patent/PT2260053E/pt unknown
- 2009-03-30 SI SI200930966T patent/SI2260053T1/sl unknown
- 2009-03-30 PL PL09727031T patent/PL2260053T3/pl unknown
- 2009-03-30 DK DK09727031.8T patent/DK2260053T3/da active
- 2009-03-30 CA CA2718148A patent/CA2718148C/en active Active
- 2009-03-30 RU RU2010139634/04A patent/RU2496788C2/ru active
- 2009-03-30 US US12/933,858 patent/US8673841B2/en active Active
- 2009-03-30 EP EP09727031.8A patent/EP2260053B1/en active Active
- 2009-03-30 WO PCT/IB2009/005351 patent/WO2009122285A1/en active Application Filing
-
2010
- 2010-09-07 IL IL208039A patent/IL208039A/en active IP Right Grant
- 2010-09-20 ZA ZA2010/06733A patent/ZA201006733B/en unknown
- 2010-12-31 HK HK10112315.1A patent/HK1146064A1/xx unknown
-
2014
- 2014-07-25 HR HRP20140716AT patent/HRP20140716T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
WO2009122285A1 (en) | 2009-10-08 |
MX2010010743A (es) | 2010-11-04 |
JP5539310B2 (ja) | 2014-07-02 |
JP2011516460A (ja) | 2011-05-26 |
IL208039A (en) | 2016-03-31 |
BRPI0910345A2 (pt) | 2015-10-06 |
KR101558404B1 (ko) | 2015-10-08 |
EP2626364A1 (en) | 2013-08-14 |
DK2260053T3 (da) | 2014-06-23 |
CN101983205B (zh) | 2015-08-19 |
ZA201006733B (en) | 2011-06-29 |
AU2009233429B2 (en) | 2014-02-13 |
CA2718148A1 (en) | 2009-10-08 |
NZ587817A (en) | 2012-05-25 |
US8673841B2 (en) | 2014-03-18 |
BRPI0910345B1 (pt) | 2021-08-17 |
PT2260053E (pt) | 2014-08-29 |
US20110044905A1 (en) | 2011-02-24 |
RU2496788C2 (ru) | 2013-10-27 |
CN101983205A (zh) | 2011-03-02 |
WO2009122285A8 (en) | 2009-12-10 |
ES2488992T3 (es) | 2014-09-01 |
IL208039A0 (en) | 2010-12-30 |
SI2260053T1 (sl) | 2014-08-29 |
AU2009233429A1 (en) | 2009-10-08 |
KR20110005705A (ko) | 2011-01-18 |
EP2260053A1 (en) | 2010-12-15 |
HK1146064A1 (en) | 2011-05-13 |
PL2260053T3 (pl) | 2014-11-28 |
RU2010139634A (ru) | 2012-05-10 |
EP2260053B1 (en) | 2014-05-14 |
CA2718148C (en) | 2017-11-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20140716T1 (hr) | Analozi oksitocina | |
JP2013543492A5 (hr) | ||
RU2016143751A (ru) | Фармацевтическая композиция | |
JP6816098B2 (ja) | 粘膜炎症を抑制するためのイガイ接着タンパク質生成物及びその使用 | |
ES2608850T3 (es) | Composiciones anestésicas termogelificantes | |
CL2017000830A1 (es) | Formulación estable que comprende un azúcar no reductora, un anticuerpo anti-s4b7 y al menos un aminoácido libre; un método para preparar dicha formulación; uso de dicha formulación para tratar una enfermedad inflamatoria del intestino. | |
HRP20160189T1 (hr) | Liječenje crohnove bolesti lakvinimodom | |
US20160136231A1 (en) | Topical formulations of chemerin c15 peptides for the treatment of dermatological conditions | |
JP2011516460A5 (hr) | ||
WO2008116890A3 (en) | Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders | |
JP2011225596A5 (hr) | ||
AU2020202835B2 (en) | Compositions and methods for inhibiting inflammation and diseases using an alginic acid-based antimicrobial compound | |
RU2011134033A (ru) | Лекарственная форма для чресслизистого перорального введения анальгетических и/или антиспазматических молекул | |
US20210128514A1 (en) | Method and compositions for treatment and prevention of broad spectrum virus ailments comprising a calcium channel blocker or a calmodulin blocker | |
JP2018528259A5 (hr) | ||
JP2012526099A5 (hr) | ||
RU2018125252A (ru) | Синергическая комбинация пирролидонкарбоновой кислоты и/или ее солей и гиалуроновой кислоты и/или ее солей для применения в лечении и/или профилактике сухости и раздражения слизистых оболочек, и связанные фармацевтические композиции | |
CN101642467A (zh) | 长效消毒膏 | |
RU2017114677A (ru) | Перорально распадающаяся твердая фармацевтическая единица дозирования, содержащая контролирующее родовую деятельность вещество | |
JP2007291073A (ja) | 痔疾用噴霧製剤 | |
CN104606212A (zh) | 一种避孕及杀微生物双功能阴道复合温敏水凝胶制剂及其制备方法 | |
CN110121334A (zh) | 三萜类化合物的避孕药用途 | |
ES2363539T3 (es) | Composición farmacéutica para el tratamiento de la xerostomía. | |
JP2019507195A5 (hr) | ||
RU2018143557A (ru) | Карбоновые кислоты, предназначенные для применения в раннем детстве |